JP2021502416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502416A5 JP2021502416A5 JP2020544565A JP2020544565A JP2021502416A5 JP 2021502416 A5 JP2021502416 A5 JP 2021502416A5 JP 2020544565 A JP2020544565 A JP 2020544565A JP 2020544565 A JP2020544565 A JP 2020544565A JP 2021502416 A5 JP2021502416 A5 JP 2021502416A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- patient
- cells
- cancer
- chain sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 claims 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 6
- 201000009030 Carcinoma Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 108010057840 ALT-803 Proteins 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 102100030704 Interleukin-21 Human genes 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 208000025696 NK cell deficiency Diseases 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000000409 cytokine receptor agonist Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 108010074108 interleukin-21 Proteins 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- -1 melfaran Chemical compound 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- 229960000237 vorinostat Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229950006344 nocodazole Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000002483 superagonistic effect Effects 0.000 claims 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 1
- 229950007866 tanespimycin Drugs 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023181486A JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
| JP2025115696A JP2025148435A (ja) | 2017-11-03 | 2025-07-09 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581380P | 2017-11-03 | 2017-11-03 | |
| US62/581,380 | 2017-11-03 | ||
| US201762592778P | 2017-11-30 | 2017-11-30 | |
| US62/592,778 | 2017-11-30 | ||
| PCT/US2018/059039 WO2019090134A1 (en) | 2017-11-03 | 2018-11-02 | Monoclonal antibody neo-201 for the treatment of human carcinomas |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181486A Division JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502416A JP2021502416A (ja) | 2021-01-28 |
| JP2021502416A5 true JP2021502416A5 (enExample) | 2021-12-02 |
| JP7437307B2 JP7437307B2 (ja) | 2024-02-22 |
Family
ID=66332711
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544565A Active JP7437307B2 (ja) | 2017-11-03 | 2018-11-02 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
| JP2023181486A Active JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
| JP2025115696A Pending JP2025148435A (ja) | 2017-11-03 | 2025-07-09 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023181486A Active JP7712338B2 (ja) | 2017-11-03 | 2023-10-20 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
| JP2025115696A Pending JP2025148435A (ja) | 2017-11-03 | 2025-07-09 | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11767367B2 (enExample) |
| EP (1) | EP3735423A4 (enExample) |
| JP (3) | JP7437307B2 (enExample) |
| CN (3) | CN119587690A (enExample) |
| AU (2) | AU2018360045B2 (enExample) |
| CA (1) | CA3083467A1 (enExample) |
| WO (1) | WO2019090134A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019221544B2 (en) * | 2018-02-13 | 2025-07-10 | Precision Biologics, Inc. | Methods and compositions for targeting Treg cells |
| CN115678854A (zh) * | 2021-07-29 | 2023-02-03 | 上海中医药大学 | 一种基因工程细胞及其制备方法和应用 |
| CN119053622A (zh) * | 2022-04-12 | 2024-11-29 | 盛禾(中国)生物制药有限公司 | 一种抗ceacam5和ceacam6抗体及其应用 |
| CN116699135B (zh) * | 2022-04-29 | 2025-11-07 | 中国医学科学院肿瘤医院 | 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2585476A4 (en) * | 2010-06-22 | 2014-01-22 | Neogenix Oncology Inc | ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER |
| EP3336104A1 (en) * | 2012-12-28 | 2018-06-20 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
| PL3160498T3 (pl) * | 2014-06-30 | 2022-02-21 | Altor Bioscience Corporation | Cząsteczki na bazie IL-15 i sposoby ich zastosowania |
| WO2018218230A1 (en) * | 2017-05-26 | 2018-11-29 | Etubics Corporation | Combination immunotherapies comprising il-15 superagonists |
-
2018
- 2018-11-02 WO PCT/US2018/059039 patent/WO2019090134A1/en not_active Ceased
- 2018-11-02 CA CA3083467A patent/CA3083467A1/en active Pending
- 2018-11-02 JP JP2020544565A patent/JP7437307B2/ja active Active
- 2018-11-02 AU AU2018360045A patent/AU2018360045B2/en active Active
- 2018-11-02 CN CN202411004231.XA patent/CN119587690A/zh active Pending
- 2018-11-02 CN CN201880085205.0A patent/CN111670199B/zh active Active
- 2018-11-02 US US16/761,404 patent/US11767367B2/en active Active
- 2018-11-02 EP EP18907474.3A patent/EP3735423A4/en active Pending
- 2018-11-02 CN CN202510631395.3A patent/CN120860200A/zh active Pending
-
2023
- 2023-09-22 US US18/472,411 patent/US20240101702A1/en active Pending
- 2023-10-20 JP JP2023181486A patent/JP7712338B2/ja active Active
-
2025
- 2025-07-09 JP JP2025115696A patent/JP2025148435A/ja active Pending
- 2025-07-14 AU AU2025205420A patent/AU2025205420A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Breakthrough of solid tumor treatment: CAR-NK immunotherapy | |
| Sun et al. | CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies | |
| Hodgins et al. | Killers 2.0: NK cell therapies at the forefront of cancer control | |
| Darragh et al. | Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment | |
| Herrera et al. | Radiotherapy combination opportunities leveraging immunity for the next oncology practice | |
| JP6748221B2 (ja) | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 | |
| Harris et al. | Immuno-oncology combinations: raising the tail of the survival curve | |
| Bhalla et al. | Combining immunotherapy and radiotherapy in lung cancer | |
| Wattenberg et al. | Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy | |
| Seyedin et al. | Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models | |
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| RU2689160C2 (ru) | Противораковая таргетная иммунотерапия с применением il-12 | |
| JP2017536812A (ja) | バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞 | |
| JP2021502416A5 (enExample) | ||
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| Zhao et al. | Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma | |
| CA3128202A1 (en) | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment | |
| JP2018516881A (ja) | 癌治療のためのｎｋ細胞および抗体 | |
| US20220111069A1 (en) | Immunoswitch nanoparticles for reprogrammed t cell responses | |
| Doloff et al. | Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2 | |
| Wang et al. | Combination of cytokine-induced killer cells and programmed cell death-1 blockade works synergistically to enhance therapeutic efficacy in metastatic renal cell carcinoma and non-small cell lung cancer | |
| Guo et al. | Tumor reductive therapies and antitumor immunity | |
| Wieder et al. | Immunotherapy of melanoma: efficacy and mode of action | |
| JP2024514149A (ja) | ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用 | |
| Shebbo et al. | Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations |